Business Context and Reporting Period
The filing is a Form 8-K filed by Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc. It reports the consummation of the company’s initial public offering and related private placement on November 22, 2019; the report was filed November 27, 2019.
Key Financial Metrics and Capitalization
- The company issued 10,000,000 units at $10.00 per unit, generating $100.0 million of gross IPO proceeds.
- Each unit comprised one share of Class A common stock and one-half of a redeemable warrant.
- Each whole public warrant is exercisable for one share of Class A common stock at $11.50 per share.
- The sponsor privately purchased 4,000,000 warrants at $1.00 per warrant, generating $4.0 million of gross proceeds.
- A total of $100.0 million was deposited into a U.S.-based trust account: $98.0 million from the IPO, including $3.5 million of deferred underwriting discount, and $2.0 million from the private placement.
- The filing does not provide revenue, operating profit, net income, cash flow, margins, debt, or liquidity metrics beyond the IPO and trust-account proceeds.
Material Changes Versus Prior Comparable Period
The filing does not present a comparative operating period. The material event was the completion of the IPO and private placement, resulting in the receipt and escrow of the disclosed proceeds.
Guidance, Outlook, Risks, and Unusual Items
- The company granted underwriters an option to purchase up to an additional 1,500,000 units; the filing does not state whether the option was exercised.
- The $100.0 million trust account is maintained by Continental Stock Transfer & Trust Company as trustee.
- The filing includes an audited balance sheet as of November 22, 2019 as Exhibit 99.1.
- No operating guidance, acquisition target, management outlook, contingencies, or additional risk discussion is provided in the supplied text.
Investor Verification Checklist
- Verify the issuer identity: the supplied filing names Amplitude Healthcare Acquisition Corporation rather than Jasper Therapeutics, Inc.
- Review Exhibit 99.1 for the audited balance sheet and post-IPO liabilities, transaction costs, and equity classification.
- Confirm the amount ultimately held in the trust account and any deferred underwriting fees.
- Check whether the 1,500,000-unit underwriter over-allotment option was exercised in subsequent filings.
- Review later filings for the company’s acquisition target, redemption terms, warrant terms, and use of trust-account funds.